STAT July 10, 2024
Elaine Chen

The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes in a rare setback for the pharmaceutical giant.

The agency has requests related to the manufacturing process and the use of the insulin specifically in type 1 diabetes patients, Novo said in a statement Wednesday. The company, which had submitted an application for the drug for...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
GenAI and the revolution of drug development
Amgen starts two critical late-stage trials for weight loss drug MariTide
Patient Access To Cheaper Biosimilar Drugs Varies Significantly Across Pharmacy Benefit Managers
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
'Not just adding another drug to your pharmacy': CAR T, explained

Share This Article